Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

FOLFIRI plus panitumumab can lead to an increased PFS in colorectal cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.04.10
Views: 9002
Rating:

Dr Thierry Andre - Hopital Tenon, Paris, France

A study comparing FOLFIRI regimens with FOLFIRI plus panitumumab showed a two month increase in progression free survival among the patients with wild type KRAS treated with FOLFIRI plus panitumumab. Side effects are limited and manageable but include discomfort in the skin around the hands and feet and diarrhea.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation